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doi:10.1016/j.fjs.2012.05.003Summary Most primary colonic lymphomas are non-Hodgkin’s lymphomas, most especially
diffuse and large B-cell lymphomas, and constitute only 0.2e0.6% of all colon cancers. The
disease manifests at a median age of 55 years (range: 23e86), and patients are predominantly
male. The tumors are most frequently located in the cecum. Because endoscopic and imaging
studies always show nonspecific findings, the diagnosis should be categorized as “suspicious”.
The current treatment options for primary colonic lymphoma are inconclusive. However,
recent studies have shown a trend where surgery followed by chemotherapy enhanced patient
outcomes in those with localized disease. For disseminated disease, target therapy (rituximab)
in combination with CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and
prednisone) increases patient survival time. With advances in molecular techniques, the clas-
sification and management of lymphoma has made progress.
Copyright ª 2012, Taiwan Surgical Association. Published by Elsevier Taiwan LLC. All rights
reserved.1. Introduction
Primary colonic lymphoma (PCL) is a rare gastrointestinal
(GI) tract malignancy. The GI tract is the most common site
for the extranodal involvement of non-Hodgkin’s lymphomary, Department of Surgery,
tional Yang-Ming University,
, Taipei 11217, Taiwan.
ov.tw
ight ª 2012, Taiwan Surgical Asso(NHL), occurring in the colorectal area in about 10e20% of
all cases with extranodal GI tract involvement.1,2 Most PCLs
have a B-cell lineage and are classified as diffuse large
B-cell lymphomas (DLBCL).3 The optimal treatment for PCL
is controversial. In this review, we describe and discuss the
clinical presentations and management of PCL.
2. Definition, etiology, and pathogenesis
PCL is an extranodal NHL. As molecular techniques have
advanced, the classification of lymphomas has progressedciation. Published by Elsevier Taiwan LLC. All rights reserved.
74 S.-C. Changto include lymphoid lineages, cell types, immunopheno-
types, karyotypes, molecular characteristics, and clinical
features. The latest World Health Organization classifica-
tion recognizes five histological subtypes (Table 1).4 The
diagnosis of PCL was initially established in 1961 and
included five criteria (Table 2).5 Most PCLs have a B-cell
lineage. Among these tumors, the leading subtype is
DLBCL,6 followed by follicular lymphoma, mucosa-
associated lymphoid tissue (MALT) lymphoma (MALToma),
and mantle cell lymphoma.7,8
Because PCL is classified as NHL in most cases, the
pathogenesis of PCL is associated with the activation of
proto-oncogenes, mainly through chromosomal trans-
location. For DLBCL, cytogenetic studies have demon-
strated that chromosomal 3q27 alterations, specifically the
location of the BCL-6 gene, are abnormalities in 35% of
cases. MALToma is associated with Helicobacter pylori
infection.8 It has been suggested that gastric MALT responds
to antigen stimulation by H pylori. The eradication of
H pylori results in the regression of MALT. The most
common genetic alteration of MALT-NHL is the
t(11;18)(q21;21) translocation, which occurs in about 50%
of patients, and fuses the API2 gene, which encodes an
inhibitor of apoptosis.9 The genetic hallmark of follicular
lymphoma (FL) is chromosomal translocations involving the
BCL-2 gene, which is located at 18q21; these translocations
are detected in 80e90% of patients with PCL (Fig. 2).10
3. Clinical presentation and diagnosis
PCLcases constitute 0.2e0.6%of all reported cases of colonic
cancers. The series reported by Taipei-Veterans General
Hospital (Taipei-VGH) gives a figure of 0.42% (29 of 6944).11
The time of onset for PCL varies in different studies, but
the median age of onset is 55 22 years (range: 23e86
years). Men are affected twice as often as women. The
articles in the literature and the Taipei-VGH series indicate
that more than half of PCL patients report abdominal pain,
followed by bloody or tarry stool (30%) and a weight loss
(25%).2,12 The most frequent tumor location is the cecum,
probably due to the large amount of lymphoid tissue in that
region.2,12 The morphology of PCLs is variable, resulting in
a wide range of radiological and endoscopic features,
including mass lesions, narrowing of the lumen, ulceration,
irregularity of the mucosa, and aphthous lesions.13e15
Endoscopy usually reveals nonspecific colitis or an ulcer;
mass lesions are unusual (Fig. 1B). Focal PCL, which is char-
acterized by infiltrative spread that arises from the submu-
cosa, results in the uniform thickening of the cecal wall and
often spreads into the terminal ileum. The morphological
appearance could consist of smooth stricturing lesions,
a circumferential infiltrative form accompanied byTable 1 2008 World Health Organization classification of lymph
1) Mature B-cell neoplasms
2) Mature T-cell and nature killer cell neoplasms
3) Hodgkin’s lymphoma
4) Histiocytic and dendritic cell neoplasms
5) Posttransplant lymphoproliferative disordersulceration, a cavitating mass, or mucosal fold thickening.
Diffuse lesions also occur, which can be ulcerative or nodular,
and are relatively small (usually< 2 cm). Endoscopic findings
are classified by ulceration, infiltration, and the presence of
a mass.16 For B-cell lymphomas, the most common endo-
scopic type is a fungatingmass (54.0%). ForT-cell lymphomas,
themost commonfindings areulcerative or ulcero-infiltrative
lesions (80.0%).17 Imaging studies sometimes show that
a lymphoma forms an annular napkin ring-like lesion that
mimics carcinoma (Fig. 1A).18
When a computed tomography (CT) scan reveals the
presence of an infiltrative process accompanied by
enlarged lymph nodes in the abdomen or pelvis, lymphoma
should be the primary consideration in the differential
diagnosis and must be excluded by endoscopic biopsy.
Nevertheless, without the presence of enlarged lymph
nodes it is difficult to distinguish this type of tumor from
primary adenocarcinoma.19 The potential role of positron-
emission tomography for the diagnosis and follow-up of
patients with lymphoma has yet to be established.
4. Staging and management
The Ann Arbor staging system, originally used for Hodgkin’s
disease, is now widely used for NHL.4 The extent of the
disease is classified as stage IeIV according to the distri-
bution of disease. For stage I, the disease involves a single-
node region. Stage II disease involves two or more node
regions on the same side of the diaphragm; the involvement
of node regions on both sides of the diaphragm defines
stage III. Diffuse involvement of the extralymphatic organs
with or without node regions is classified as stage IV.
Furthermore, localized extralymphatic disease is described
by the use of the subscript letter “E”.
For PCL, the disease stage at the time of diagnosis varies
in different publications. A 371-patient study in Germany
showed that approximately 90% of the patients with GI NHL
had stage IE/IIE disease.7 On the other hand, a 244-patient
study from the USA reported that over half of the patients
presented with stage IV disease.8 In the Taipei-VGH series,
18 (67%) patients had early-stage (stage I or II) and nine
(33%) had late-stage disease.12 Overall, the 3- and 5-year
survival rates for PCL patients were 60.8% and 47.3%,
respectively.
NHL types can be separated into two distinct prognostic
groups: indolent and aggressive. The indolent group
responds well to radiation therapy and demonstrates a good
clinical prognosis when diagnosed in the early stages.20,21
The aggressive subtype of NHL generally has a less favor-
able prognosis and requires more intensive therapy.
However, studies of the factors affecting the survival of PCL
patients are inconclusive, though the stage at diagnosis,omas.
Table 2 Criteria for the diagnosis of primary colonic lymphoma.
1) No palpable superficial lymphadenopathy on initial examination
2) No obvious enlargement of the mediastinal lymph nodes on chest X-ray
3) White blood cell count within normal limits
4) Aominant bowel lesion on laparotomy
5) Involvement of only the lymph nodes in the immediate vicinity of the primary lesion
Primary colonic lymphoma 75histological grade, and any complications that result in
urgent surgery do have an impact on survival.8,22
Chemotherapy remains the basis of treatment for
rapidly proliferating aggressive lymphomas because most
NHLs present as systemic disease.23e25 The CHOP chemo-
therapeutic regimen (cyclophosphamide, doxorubicin,
vincristine, and prednisone) remains as the first-line
therapy for all moderate and high-grade B-cell
lymphomas. Rituximab, a chimeric anti-CD20 monoclonal
antibody, induces the death of normal and malignant
B-cells that express the cell-surface molecule CD20.
Treatment with rituximab as a single agent results in
significant responses in patients with almost every subtype
of B-cell lymphoma.28 For low-grade lymphomas, a single
alkylating agent and CVP (cyclophosphamide, vincristine,
and prednisone) are the preferred choice of treatment.26Figure 1 A 72-year-old female patient presented with right lowe
a mass-like lesion in the cecal region. (Panel A) The colonoscopic fin
(Panel B) The patient underwent an exploratory laparotomy and a r
annular infiltrative mass, 5  5 cm in size, in the ileocecal area.The role of surgery is to establish a diagnosis of extra-
nodal NHL. However, there are some controversies
regarding the role of surgery for managing GI tract
lymphoma. For the treatment of primary gastric DLBCL, the
role of surgery has diminished and the treatment strategy
has moved toward organ preservation because surgical
resection is not superior to chemotherapy plus radio-
therapy.27 However, two specific problems with intestinal
DLBCL enhance the role of surgical resection for managing
intestinal lymphomas: difficulties in the preoperative
pathological diagnosis and the risk of intestinal perforation
(Fig. 2). Because the incidence of PCL is low, there has
never been a controlled randomized trial to define the role
of surgery for the treatment of PCL. Some authors have
suggested that systemic chemotherapy alone should be
the standard treatment, with surgery reserved forr quadrant pain, and the computed tomographic image showed
ding showed an infiltrative mass with an inflammatory exudate.
ight hemicolectomy. (Panel C) The operative finding showed an
Figure 2 Based on the pathological results, the final diag-
nosis was primary colonic lymphoma. Panel A: Homogenous
large round cell infiltration (as shown by the arrow head)
within the tumor (20). Panel B: Positive staining of BCL-2
indicates that the possible genetic defect is a BCL-2
translocation.
76 S.-C. Changcomplications such as perforation, obstruction, and
bleeding,7,8 whereas others believe that surgery provides
better localized disease control and improves the survival
outcome.18,29 The results of the Taipei-VGH series suggests
that for PCL patients, surgery followed by chemotherapy
produces a statistically better survival rate when compared
to chemotherapy alone. Recently, a large retrospective
cohort study in Korea showed that for patients with local-
ized disease (stage I/II), surgery plus chemotherapy yields
a lower relapse rate (15.3%) than chemotherapy alone
(36.8%).29 However, surgical resection did not provide any
significant benefit to patients with disseminated disease.
For disseminated disease, adding rituximab to CHOP (R-
CHOP) resulted in a better 3-year overall survival (59%)
compared with CHOP alone (29%). These data suggest that
R-CHOP is a better treatment for disseminated disease.
However, the addition of rituximab to CHOP failed to show
additional survival benefits regardless of localized disease,
regardless of surgery.28
Because the rate of intestinal perforation is high (> 30%)
with chemotherapy, some authors suggest that surgical
resection could prevent this complication and improvepatient outcomes.14 Nevertheless, some authors argue that
PCL originating from intestinal lymphoid tissue should be
treated as a systemic disease, and that early diagnosis and
the timely onset of chemotherapy are sufficient to achieve
adequate disease control and avoid surgery.7,8
5. Conclusions
PCL is a rare condition. The small number of patients with
various histological subtypes and different stages at diag-
nosis has resulted in uncertain treatment protocols. The
optimal management has not been established by
randomized trials. Nevertheless, recent publications show
trends toward multimodality management, with surgical
resection of the primary lesion followed by standard
chemotherapy affording better local disease control and
survival.
List of abbreviations:
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Taipei-Veterans General Hospital (Taipei-VGH).References
1. Chuang SS, Li CY. Clinicopathological features of primary
intestinal lymphoma in Taiwan: A study of 21 resected cases.
Pathol Res Pract. 2002;198:381e388.
2. Wong MT, Eu KW. Primary colorectal lymphomas. Colorectal
Dis. 2006;8:586e591.
3. Daum S, Ullrich R, Heise W, et al. Intestinal non-Hodgkin’s
lymphoma: A multicenter prospective clinical study from the
German Study Group on Intestinal non-Hodgkin’s Lymphoma.
J Clin Oncol. 2003;21:2740e2746.
4. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of
Tumours of Haematopoietic and Lymphoid Tissues. 4th ed.
Lyon, France: IARC Press; 2008.
5. Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid
tumours of the intestinal tract: Report of 37 cases with a study
of factors influencing prognosis. Br J Surg. 1961;49:80e89.
6. Koch P, del Valle F, Berdel WE, et al. Primary gastrointestinal
non-Hodgkin’s lymphoma, I: Anatomic and histologic distribu-
tion, clinical features, and survival data of 371 patients
registered in the German Multicenter Study GIT NHL 01/92.
J Clin Oncol. 2001;19:3861e3873.
7. Cai S, Cannizzo F Jr, Bullard Dunn KM, Gissa JF, Czuczman M,
Rajput A. The role of surgical intervention in non-Hodgkin’s
lymphoma of the colon and rectum. Am J Surg. 2007;193:
409e412.
8. Wotherspoon AC. Gastric lymphoma of mucosa-associated
lymphoid tissue and Helicobacter pylori. Ann Rev Med. 1998;
49:289e299.
9. Dierlamm J, Baens M, Wlodarska I, et al. The apoptosis inhib-
itor gene API2 and a novel 18q gene, MLT, are recurrently
rearranged in the t(11;18)(q21;q21) associated with mucosa-
Primary colonic lymphoma 77associated lymphoid tissue lymphomas. Blood. 1999;93:
3601e3609.
10. Chao DT, Korsmeyer SJ. BCL-2 family: Regulators of cell death.
Annu Rev Immunol. 1998;16:395e419.
11. Lai YL, Lin JK, Liang WY, Huang YC, Chang SC. Surgical resec-
tion combined with chemotherapy can help achieve better
outcomes in patients with primary colonic lymphoma. J Surg
Oncol. 2011;104:265e268.
12. Hwang WS, Yao JC, Cheng SS, Tseng HH. Primary colorectal
lymphoma in Taiwan. Cancer. 1992;70:575e580.
13. O’Connell DJ, Thompson AJ. Lymphoma of the colon: The
spectrum of radiologic changes. Gastrointest Radiol. 1978;2:
377e385.
14. Cho MJ, Ha CS, Allen PK, Fuller LM, Cabanillas F, Cox JD.
Primary non-Hodgkin lymphoma of the large bowel. Radiology.
1997;205:535e539.
15. Wang MH, Wong JM, Lien HC, Lin CW, Wang CY. Colonoscopic
manifestations of primary colorectal lymphoma. Endoscopy.
2001;33:605e609.
16. Myung SJ, Joo KR, Yang SK, et al. Clinicopathologic features of
ileocolonic malignant lymphoma: Analysis according to colo-
noscopic classification. Gastrointest Endosc. 2003;57:343e347.
17. Wyatt SH, Fishman EK, Jones B. Primary lymphoma of the colon
and rectum: CT and barium enema correlation. Abdom
Imaging. 1993;18:376e380.
18. Lee HJ, Han JK, Kim TK, et al. Primary colorectal lymphoma:
Spectrum of imaging findings with pathologic correlation. Eur
Radiol. 2002;12:2242e2249.
19. Fisher RI, Oken MM. Clinical practice guidelines: Non-Hodgkin’s
lymphomas. Cleve Clin J Med. 1995;62(Suppl 1). SI6e42, quiz
SI43e45.20. Skarin AT, Dorfman DM. Non-Hodgkin’s lymphomas: Current
classification and management. CA Cancer J Clin. 1997;47:
351e372.
21. Fan CW, Changchien CR, Wang JY, et al. Primary colorectal
lymphoma. Dis Colon Rectum. 2000;43:1277e1282.
22. Vose JM. Classification and clinical course of low-grade non-
Hodgkin’s lymphomas with overview of therapy. Ann Oncol.
1996;7(Suppl 6):S13eS19.
23. Armitage JO. Treatment of non-Hodgkin’s lymphoma. N Engl J
Med. 1993;328:1023e1030.
24. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a stan-
dard regimen (CHOP) with three intensive chemotherapy
regimens for advanced non-Hodgkin’s lymphoma. N Engl J Med.
1993;328:1002e1006.
25. Arranz R, Garcia-Alfonso P, Sobrino P, et al. Role of interferon
alfa-2b in the induction and maintenance treatment of low-
grade non-Hodgkin’s lymphoma: Results from a prospective,
multicenter trial with double randomization. J Clin Oncol.
1998;16:1538e1546.
26. Zinzani PL, Magagnoli M, Pagliani G, et al. Primary intestinal
lymphoma: Clinical and therapeutic features of 32 patients.
Haematologica. 1997;82:305e308.
27. Doolabh N, Anthony T, Simmang C, et al. Primary colonic
lymphoma. J Surg Oncol. 2000;74:257e262.
28. Lee J, Kim WS, Kim K, et al. Prospective clinical study of
surgical resection followed by CHOP in localized intestinal
diffuse large B cell lymphoma. Leuk Res. 2007;31:359e364.
29. Kim SJ, Kang HJ, Kim JS, et al. Comparison of treatment
strategies for patients with intestinal diffuse large B-cell
lymphoma: Surgical resection followed by chemotherapy
versus chemotherapy alone. Blood. 2011;117:1958e1965.
